<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04438603</url>
  </required_header>
  <id_info>
    <org_study_id>XHEC-C-2020-070-1</org_study_id>
    <nct_id>NCT04438603</nct_id>
  </id_info>
  <brief_title>The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy</brief_title>
  <official_title>The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study aims to investigate the role of IR-Seq in the diagnosis and disease&#xD;
      monitoring in patients with IgA nephropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autoimmunity may play an important role in IgA nephropathy, and previous studies have shown&#xD;
      that immune repertoire sequencing (IR-Seq) may help elucidate the dynamic changes of immune&#xD;
      repertoire (IR) in autoimmune disease states. To further explore the potential application&#xD;
      value of this technology, we will conduct a series of prospective studies to investigate the&#xD;
      role of IR-Seq in the diagnosis and disease monitoring in patients with IgA nephropathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary protein remission rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Including complete and partial remission rate of urinary protein. Complete remission criteria: post-treatment urine protein &lt;0.3 g/24h; partial remission criteria: post-treatment urine protein &lt;50% of the maximum value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour urine protein level</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum albumin level</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR (estimated using the 2009 CKD-EPI formula)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>IgAN patients at low risk of disease progression</arm_group_label>
    <description>n = 30, incipient disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IgAN patients at high risk of disease progression</arm_group_label>
    <description>n = 60, incipient disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long-term stable patients</arm_group_label>
    <description>n = 30, follow-up for at least 15 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progressive IgAN patients</arm_group_label>
    <description>n = 30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <description>n = 30</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention for incipient patients at low risk of disease progression</intervention_name>
    <description>Conservative treatment, if necessary use ACEI/ARB and titrated to the maximum tolerated dose, with a BP-lowering goal of &lt; 130/80 mm Hg</description>
    <arm_group_label>IgAN patients at low risk of disease progression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention for patients at high risk of disease progression</intervention_name>
    <description>BP-lowering goal of &lt; 125/75 mm Hg and treat with steroids or steroids combined with immunosuppressants based on optimal supportive therapy:&#xD;
If GFR&gt;60 ml/min/1.73m^2, oral prednisone 0.6-0.8 mg/kg/day ( (maximum dose 48 mg/day) for 2 months, followed by a monthly dose reduction of 8 mg for 24 weeks.&#xD;
If GFR is 30-60 ml/min/1.73m^2, intravenous cyclophosphamide (CTX) 750 mg per month per m^2 for 6 months, along with oral prednisone (at the same dose as 1); if intravenous administration is unacceptable, then the above regimen was replaced with oral mycophenolate mofetil 500 mg bid for 24 weeks.</description>
    <arm_group_label>IgAN patients at high risk of disease progression</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples; Blood samples taken using PAXgene vacuum blood collection tubes&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai&#xD;
        Jiao Tong University Affiliated Sixth People's Hospital, RenJi Hospital, Shanghai Zhongshan&#xD;
        Hospital, Longhua Hospital Shanghai University of Traditional Chinese Medicine and Shanghai&#xD;
        East Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. IgA nephropathy:&#xD;
&#xD;
          1. Age: 18-80 years.&#xD;
&#xD;
          2. Patients diagnosed with primary IgA nephropathy by renal biopsy.&#xD;
&#xD;
          3. Estimated glomerular filtration rate (using the 2009 CKD-EPI formula)&#xD;
             ≥30ml/min/1.73/m^2.&#xD;
&#xD;
          4. Obtain informed consent from patients. 2. Healthy Control: Gender, age and ethnicity&#xD;
             matched health volunteers. 3. IgAN patients were further divided into 4 groups, as&#xD;
             defined below:&#xD;
&#xD;
        1) Long-term stable patients:&#xD;
&#xD;
        Follow-up for at least 15 years and meet at least one of the following:&#xD;
&#xD;
          1. Annual eGFR loss rate &lt;3ml/min/1.73m^2.&#xD;
&#xD;
          2. eGFR&gt;90ml/min/1.73m^2. 2) Non-progressive IgAN patients:&#xD;
&#xD;
        Meet at least one of the following:&#xD;
&#xD;
          1. eGFR decrease of more than 50% from baseline (in the absence of other possible causes&#xD;
             of kidney damage).&#xD;
&#xD;
          2. Annual eGFR loss rate &gt;5ml/min/1.73m^2.&#xD;
&#xD;
          3. Progress to ESRD. 3) IgAN patients at low risk of disease progression: Proteinuria ≤&#xD;
             1g/24h after 3 months of optimized supportive care. 4) IgAN patients at high risk of&#xD;
             disease progression: Proteinuria &gt; 1g/24h despite 3 months of optimized supportive&#xD;
             care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Kidney biopsy shows crescentic IgAN or MCD-IgAN.;&#xD;
&#xD;
          2. Patients with secondary IgAN;&#xD;
&#xD;
          3. During pregnancy or lactation;&#xD;
&#xD;
          4. After kidney transplantation;&#xD;
&#xD;
          5. More than one serious acute infection in the psat 12 months;&#xD;
&#xD;
          6. Chronic infection;&#xD;
&#xD;
          7. Use of glucocorticosteroids and other immunosuppressive drugs within the last 6&#xD;
             months;&#xD;
&#xD;
          8. Incomplete medical history or clinical data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Gengru</last_name>
      <phone>+86-13917983703</phone>
      <email>jianggeng-ru@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IgA Nephropathy</keyword>
  <keyword>IR-Seq</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

